Literature DB >> 9291651

Compliance of secondary prophylaxis for controlling rheumatic fever and rheumatic heart disease in a rural area of northern India.

R Kumar1, J S Thakur, A Aggarwal, N K Ganguly.   

Abstract

This study was conducted in a community development block of a district in Haryana to evaluate the compliance of secondary prophylaxis for controlling rheumatic fever (RF) and rheumatic heart disease (RHD). The patients were interviewed using a semi-structured schedule at home. Currently 110 patients are registered in RF/RHD registry of which 53 (48.2%) are males. Mean age of patients was 18.4 +/- 8.6 years, ranging from 6 to 50 years with majority (48, 43.7%) of patients in the age groups of 6-15 and 16-25 years. Out of 110 patients, more than 90 percent had taken 11 out of the 12 due doses of secondary prophylaxis every year in the last eight years of the programme except in 1995 when 92 (83.6%) patients took the prophylactic doses. Only one patient reported recurrent attacks of rheumatic fever after irregular secondary prophylaxis. Eighteen (16.4%) patients were defaulters at the time of interview and were motivated to take secondary prophylaxis regularly. Ninety-seven (88.2%) patients were satisfied with the ongoing programme. In developing countries, it is possible to successfully apply a secondary prevention programme for control of RF/RHD by using existing health infrastructure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291651

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  9 in total

1.  Secondary prophylaxis is important for the prevention of recurrent rheumatic fever in the Pacific.

Authors:  Andrew C Steer; Samantha Colquhoun; Joseph Kado; Jonathan R Carapetis
Journal:  Pediatr Cardiol       Date:  2011-08       Impact factor: 1.655

2.  Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever.

Authors:  Christina F Pelajo; Jorge M Lopez-Benitez; Juliana M Torres; Sheila Kf de Oliveira
Journal:  Pediatr Rheumatol Online J       Date:  2010-07-26       Impact factor: 3.054

3.  Rheumatic Heart Disease Patients' Adherence to Secondary Prophylaxis and Associated Factors at Hospitals in Jimma Zone, Southwest Ethiopia: A Multicenter Study.

Authors:  Alinur Adem; Tadesse Dukessa Gemechu; Habtemu Jarso; Wondu Reta
Journal:  Patient Prefer Adherence       Date:  2020-12-04       Impact factor: 2.711

4.  Global research priorities in rheumatic fever and rheumatic heart disease.

Authors:  Jonathan R Carapetis; Liesl J Zühlke
Journal:  Ann Pediatr Cardiol       Date:  2011-01

5.  Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review.

Authors:  Priya M Kevat; Benjamin M Reeves; Alan R Ruben; Ronny Gunnarsson
Journal:  Curr Cardiol Rev       Date:  2017

6.  Compliance to the secondary prophylaxis and awareness of rheumatic heart disease: A cross-sectional study in low-income province of India.

Authors:  Arun Prasad; Abhiranjan Prasad; Birendra K Singh; Sanjeev Kumar
Journal:  J Family Med Prim Care       Date:  2020-03-26

7.  Adherence rates and risk factors for suboptimal adherence to secondary prophylaxis for rheumatic fever.

Authors:  Priya M Kevat; Ronny Gunnarsson; Benjamin M Reeves; Alan R Ruben
Journal:  J Paediatr Child Health       Date:  2020-12-19       Impact factor: 1.954

8.  Determinants of poor adherence to secondary antibiotic prophylaxis for rheumatic fever recurrence on Lifou, New Caledonia: a retrospective cohort study.

Authors:  Brunelle Gasse; Noémie Baroux; Bernard Rouchon; Jean-Michel Meunier; Isabelle De Frémicourt; Eric D'Ortenzio
Journal:  BMC Public Health       Date:  2013-02-12       Impact factor: 3.295

9.  Benzathine penicillin adherence for secondary prophylaxis among patients affected with rheumatic heart disease attending Mulago Hospital.

Authors:  Charles Musoke; Charles Kiiza Mondo; Emmy Okello; Wanzhu Zhang; Barbara Kakande; Wilson Nyakoojo; Juergen Freers
Journal:  Cardiovasc J Afr       Date:  2013-05       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.